LONDON (Alliance News) - The following UK shares received analyst recommendations Monday morning:
----------
FTSE 100
----------
BARCLAYS RAISES RSA TO 'OVERWEIGHT' ('EQUAL WEIGHT') - TARGET 538 (102) PENCE
----------
SOCGEN CUTS ROLLS-ROYCE TO 'SELL' ('HOLD') - TARGET 950 (1070) PENCE
----------
SOCGEN RAISES GLAXOSMITHKLINE PRICE TARGET TO 2100 (2075) PENCE - 'BUY'
----------
HSBC RAISES BG GROUP PRICE TARGET TO 1425 (1260) PENCE - 'OVERWEIGHT'
----------
EXANE RAISES RECKITT BENCKISER PRICE TARGET TO 4900 (4500) PENCE - 'UNDERPERFORM'
----------
EXANE BNP CUTS BHP BILLITON PRICE TARGET TO 1850 (2000) PENCE - 'NEUTRAL'
----------
EXANE BNP CUTS RIO TINTO PRICE TARGET TO 3800 (4070) PENCE - 'OUTPERFORM'
----------
CREDIT SUISSE RAISES WEIR GROUP PRICE TARGET TO 2540 (2390) PENCE - 'NEUTRAL'
----------
FTSE 250
----------
GOLDMAN RAISES HISCOX PRICE TARGET TO 607 (606,74) PENCE - 'SELL'
----------
HSBC RAISES PARAGON GROUP PRICE TARGET TO 380 (335) PENCE - 'NEUTRAL'
----------
BARCLAYS RAISES DEBENHAMS TO 'EQUAL WEIGHT' ('UNDERWEIGHT') - TP 73 (64) PENCE
----------
CREDIT SUISSE CUTS FENNER PRICE TARGET TO 405 (490) PENCE - 'OUTPERFORM'
----------
CREDIT SUISSE RAISES HALMA PRICE TARGET TO 665 (620) PENCE - 'OUTPERFORM'
----------
CREDIT SUISSE RAISES LAIRD PRICE TARGET TO 270 (215) PENCE - 'UNDERPERFORM'
----------
CREDIT SUISSE RAISES MORGAN ADVANCED MATERIALS TP TO 310 (270) PENCE - 'UNDERPEFORM'
----------
CREDIT SUISSE RAISES ROTORK PRICE TARGET TO 2600 (2450) PENCE - 'NEUTRAL'
----------
CREDIT SUISSE RAISES SENIOR PLC PRICE TARGET TO 335 (315) PENCE - 'OUTPERFORM'
----------
CANACCORD CUTS IG GROUP PRICE TARGET TO 659 (711) PENCE - 'BUY'
----------
NUMIS CUTS CRODA PRICE TARGET TO 2554 (2575) PENCE - 'HOLD'
----------
CANACCORD CUTS IG GROUP PRICE TARGET TO 659 (711) PENCE - 'BUY'
----------
MAIN MARKET AND AIM
----------
GOLDMAN CUTS SHANKS GROUP PRICE TARGET TO 119 (122) PENCE - 'NEUTRAL'
----------
LIBERUM INITIATES NCC GROUP WITH 'BUY' - TARGET 220 PENCE
----------
Investec Cuts Majestic Wine To Add from Buy, PT 460p
----------
Copyright 2014 Alliance News Limited. All Rights Reserved.
GSK's Jemperli sees success in endometrial cancer trial
(Sharecast News) - GSK reported encouraging outcomes from part one of the 'RUBY' phase three trial evaluating the efficacy of 'Jemperli', or dostarlimab, with standard chemotherapy for treating adult patients with advanced or recurrent endometrial cancer on Monday.
Read more